FDA 483 - AGC Biologics, Inc.
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of AGC Biologics, a drug substance manufacturing facility in Bothell, WA, revealed six significant observations. The firm was cited for operating a harvest filtration unit in an unvalidated state and conducting incomplete root cause investigations for various process deviations. Additionally, the inspection found inadequate microbial control during manufacturing, insufficient quality assurance oversight, inconsistencies between SOPs and batch records, and a failure to follow approved validation protocols.
- Company
- AGC Biologics, Inc.
- Product Type
- Drugs
ID · 361f2f05-4042-44c5-985a-e95863e25cc0